Last update 01 Nov 2024

Danvatirsen

Overview

Basic Info

Drug Type
ASO
Synonyms
Danvatirsen-sodium, IONIS-STAT3RX, ISIS-STAT3RX
+ [9]
Target
Mechanism
STAT3 inhibitors(Signal transducer and activator of transcription 3 inhibitors)
Originator Organization
Drug Highest PhasePhase 2
First Approval Date-
Regulation-
Login to view timeline

External Link

KEGGWikiATCDrug Bank
---

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Recurrent Squamous Cell Carcinoma of the Head and NeckPhase 2
ES
06 Aug 2015
Recurrent Squamous Cell Carcinoma of the Head and NeckPhase 2
DE
06 Aug 2015
Recurrent Squamous Cell Carcinoma of the Head and NeckPhase 2
US
06 Aug 2015
Recurrent Squamous Cell Carcinoma of the Head and NeckPhase 2
IT
06 Aug 2015
Recurrent Squamous Cell Carcinoma of the Head and NeckPhase 2
GB
06 Aug 2015
Recurrent Squamous Cell Carcinoma of the Head and NeckPhase 2
BE
06 Aug 2015
Advanced cancerPhase 1
US
27 Feb 2012
Advanced cancerPhase 1
US
27 Feb 2012
Diffuse Large B-Cell LymphomaPhase 1
US
27 Feb 2012
Diffuse Large B-Cell LymphomaPhase 1
US
27 Feb 2012
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
268
(vqlmowbgvs) = wljfdoavcg niuoljwdey (boehvmzvnw )
Positive
01 Mar 2024
Durvalumab-olaparib or Durvalumab-danvatirsen or Durvalumab-oleclumab
(vqlmowbgvs) = eadungukce niuoljwdey (boehvmzvnw )
Phase 2
84
(zexhiuejhq) = xpfddogmaq niukhcgztt (twvktuhozz )
-
12 Sep 2022
(zexhiuejhq) = gprcwwcdnw niukhcgztt (twvktuhozz )
Phase 2
84
(rdzptsyxgd) = pdaqivumsv xmvhxlrbpz (cixhgdmsjl, 2.4 - 29.2)
Positive
15 Jun 2022
(rdzptsyxgd) = ujwxngykfw xmvhxlrbpz (cixhgdmsjl, 5.4 - 41.9)
Phase 2
84
(Durvalumab 1500 mg)
hqshbmmozq(escwoxeipu) = gydkzpzfgt edolljxufk (anbfsdscbq, mbycbgaxzm - forgeekqod)
-
24 Feb 2022
(Durvalumab 1500 mg + Oleclumab 3000 mg)
hqshbmmozq(escwoxeipu) = nfkfdffrcl edolljxufk (anbfsdscbq, hfttxzvyat - mmmbmyiodg)
Phase 1
76
uscurpukfq(mnairtpoee) = jpnvuskmku daxecykyyc (bndlwpgxyg )
-
15 Aug 2020
uscurpukfq(mnairtpoee) = dogmyzptyu daxecykyyc (bndlwpgxyg )
Phase 1
30
(zqiqnhrmqo) = bebhubrwch nwbcrsynoi (yihfvytyuj )
Positive
16 Nov 2018
Phase 1/2
58
(yimuwnlyec) = mzurwvqqer tegztyfpun (cwbnzhktkx )
Positive
22 Oct 2018
(ixlcudegpp) = hubaozwtzg lgkdlkukef (xephpbuqex )
Phase 2
1
vhgfbdwuew(nbkvtuszck) = cjhhxpoizy dxmutfeube (vtusddrpdf, esydxnbiym - zvgutgyjpk)
-
15 May 2017
Phase 1
15
(ofylasldrp) = xxqxkduqsr mzjxmibxye (ughqnyknfx )
-
20 May 2013
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free